Advances in diabetes for the millennium: Understanding insulin resistance CME

MedGenMed Medscape General Medicine

Volumn 6, Issue 3 SUPPL., 2004, Pages

  Gerich, John E ^b   Dailey, George ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN DERIVATIVE; INSULIN SENSITIZING AGENT; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ARTICLE; CELL FUNCTION; CLINICAL TRIAL; CONTINUING EDUCATION; DETERIORATION; DISEASE EXACERBATION; DRUG EFFICACY; GENETIC DISORDER; GLUCOSE TOLERANCE; HEREDITY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; MEDICAL EDUCATION; MONOZYGOTIC TWINS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; TREATMENT FAILURE; TWIN DISCORDANCE; UNITED KINGDOM; GENETICS; METABOLISM; REVIEW;

DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS;

EID: 27444440548     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Yki-Jarvinen H. Glucose toxicity. Endocr Rev. 1992;13:415-431.
2. Gerich J. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev. 1998;19:491-503.
3. Cerasi E, Luft R. Insulin response to glucose infusion in diabetic and nondiabetic monozygotic twin pairs: genetic control of insulin response. Acta Endocrinol (Copenh). 1967;55:330-345.
4. Barnett A, Spiliopoulos A, Pyke D, Stubbs W, Burrin J, Alberti K. Metabolic studies in unaffected co-twins of noninsulin dependent diabetics. BMJ. 1981;282:1656-1658.
5. Pyke D, Taylor K. Glucose tolerance and serum insulin in unaffected identical twins of diabetics. BMJ. 1967;4:21-22.
6. Vaag A, Henriksen J, Madsbad S, Holm N. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;95:690-698.
7. Beck-Nielsen H, Pedersen O, Lindskov H. Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year. Acta Endocrinol (Copenh). 1979;90:103-112.
8. U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44:1249-1258.
9. Hales C, Barker D. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia. 1992;35:595-601.
10. Froguel P, Velho G. Molecular genetics of maturity-onset diabetes of the young. Trends Endocrinol Metab.1999;10:142-146.
11. McGarry J, Dobbins R. Fatty acids, lipotoxicity and insulin secretion. Diabetologia. 1999;42:128-138.
12. Cline G, Petersen K, Krssak M, et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med. 1999;341:240-246.
13. Dohm GL, Tapscott E, Pories W, et al. An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. J Clin Invest. 1988;82:486-494.
14. Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in noninsulin-dependent diabetes mellitus. N Engl J Med. 1992;327:707-713.
15. Taylor R, Price T, Katz L, Shulman R, Shulman G. Direct measurement of change in muscle glycogen concentration after a mixed meal in normal subjects. Am J Physiol. 1993;265:E224-E229.
16. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1996;46:3-10.
17. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med. 1992;326:22-29.
18. Arner P, Pollare T, Lithell H. Different aetiologies of type 2 (noninsulin-dependent) diabetes mellitus in obese and nonobese subjects. Diabetologia. 1991;34:483-487.
19. Banerji M, Lebovitz H. Insulin-sensitive and insulin-resistant variants in NIDDM. Diabetes. 1989;38:784-792.
20. Haffner S, Miettinen H, Gaskill S, Stern M. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes. 1995;44:1386-1391.
21. Lillioja S, Mott D, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med. 1993;329:1988-1992.
22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
23. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
24. DeFronzo R. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.